1. pacemaker1658
2. dakotamonrow
3. akwench
4. gnickg9585
5. forthayer
1.pacemaker1658 01/31/2018
Beats EPS estimates by $0.07 and beats on revenues
2.akwench 01/22/2018
Have to read the details of it
3.dakotamonrow 01/22/2018
FDA approval
4.pacemaker1658 05/17/2018
Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
5.pacemaker1658 02/26/2018
Receives additional FDA approval for VerzenioTM (abemaciclib), as initial treatment for advanced breast cancer
6.pacemaker1658 01/31/2018
Sees FY18 $4.81-4.91 vs $4.67
7.dakotamonrow 02/01/2018
verified - BMO Capital
8.akwench 02/22/2018
Options DD
9.forthayer 04/04/2018
BMO Capital sets PT at $74
10.henboty 06/05/2018
FDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irre
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW